A Multicenter Phase I Ascending Dose Study of DCC-2701 to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Solid Tumors
The purpose of this study is to find the highest dose of the investigational drug DCC-2701 that can be given safely in patients with advanced solid tumors containing MET or TRK genetic mutations. These mutations may fuel cancer growth. DCC-2701 is designed to block growth signals in tumors with MET or TRK mutations.
DCC-2701 is taken orally (by mouth).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have an advanced solid tumor that cannot be successfully treated with standard therapies and which contains a MET or TRK mutation.
- Patients must recover from the serious side effects of prior therapies before entering the study.
- Patients must be able to walk and do routine activities for more than half of their normal waking hours.
- This study is for patients age 18 and older.
For more information and to inquire about eligibility for this study, please contact Dr. Alexander Drilon at 646-888-4206.